
Alessandro Maselli is currently President and Chief Executive Officer of Catalent Pharma Solutions and a member of its Board.
Alessandro Maselli is currently President and Chief Executive Officer of Catalent Pharma Solutions and a member of its Board.
Q1 2025 EBITDA decreased 17% to $353 million. Excluding the impact of business combinations and other special items, Adjusted EBITDA was $365 million versus $443 million in the same quarter last year.
The Middletown closure will affect approximately 130 employees.